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Abstract— Privacy is a major concern in sharing human subject data to researchers for secondary analyses. A simple binary 
consent (opt-in or not) may significantly reduce the amount of sharable data, since many patients might only be concerned about 
a few sensitive medical conditions rather than the entire medical records. We propose event-level privacy protection, and develop 
a feature ablation method to protect event-level privacy in electronic medical records. Using a list of 13 sensitive diagnoses, we 
evaluate the feasibility and the efficacy of the proposed method. As feature ablation progresses, the identifiability of a sensitive 
medical condition decreases with varying speeds on different diseases. We find that these sensitive diagnoses can be divided 
into 3 categories: (1) 5 diseases have fast declining identifiability (AUC below 0.6 with less than 400 features excluded); (2) 7 
diseases with progressively declining identifiability (AUC below 0.7 with between 200 and 700 features excluded); and (3) 1 
disease with slowly declining identifiability (AUC above 0.7 with 1000 features excluded). The fact that the majority (12 out of 13) 
of the sensitive diseases fall into the first two categories suggests the potential of the proposed feature ablation method as a 
solution for event-level record privacy protection. 
Index Terms—healthcare privacy, data sharing, machine learning, feature ablation, Electronic Health Records  
——————————      —————————— 
1 INTRODUCTION
ata privacy is a major concern in biomedical data 
sharing and analysis. Electronic healthcare records 
(EHRs) contain sensitive information that can risk 
the privacy of individuals, which therefore needs to be 
carefully processed. Despite the policies on protecting data 
privacy, research has demonstrated that the privacy risk of 
re-identification still exists even the data are HIPAA 
(Health Insurance Portability and Accountability Act) [1] 
de-identified [2-4]. In order to keep sensitive patient infor-
mation confidential, we need to develop technical solu-
tions to safeguard patients’ privacy in EHRs. This is a chal-
lenging task and we need to consider the trade-off between 
privacy and utility. We may consider adopting strong pri-
vacy-preserving solutions and publish only a few data 
points for research, which might hurt the validity of the re-
search outcomes. On the other hand, if we do not suffi-
ciently suppress sensitive information, patient identity can 
be at risk [5, 6]. This is often a dilemma to the biomedical 
and privacy research community. 
There is a sweet spot, however, if we carefully investi-
gate this problem, which might allow us to develop novel 
solutions to strike the right balance between privacy and 
utility. That is, in reality, patients do not view all their data 
being equally sensitive because most of the time only a 
small proportion might be deemed confidential as re-
ported in several studies that have looked into 
personalized protection of sensitive information [7, 8]. We 
are inspired by this idea and believe it is possible to sepa-
rate sensitive information from the medical records of in-
dividual patients in a fine-grained manner (e.g., a patient 
may be reluctant to reveal his/her depression but willing 
to disclose other conditions) to support event-level privacy 
protection. With the ability to remove sensitive diseases 
and their associated conditions, patients can have more op-
tions regarding how they want to share their data and 
might encourage data sharing with reduced privacy con-
cerns. This seemingly simple idea is indeed non-trivial be-
cause suppression of explicitly sensitive information (e.g., 
diagnosis) is not sufficient to protect patient privacy. For 
example, patients with depressive disorder (ICD-9-CM Di-
agnosis Code 311) might take anti-depressants like cital-
opram, escitalopram, and paroxetine, among other medi-
cations. The medication events could lead to the identifica-
tion of the disease event even the diagnosis code 311 is re-
moved. 
In data privacy, many state-of-the-art approaches 
adopt differential privacy [9], a strong crypto-motivated 
criterion, to mask sensitive information by noise perturba-
tion. Under this principle, researchers have developed par-
ametric, non-parametric, and semiparametric models [10-
13] to protect information dissemination. A recent survey 
summarizes a number of methods and their biomedical ap-
plications [14]. However, there are still limitations with 
these approaches. First, the noise added to the data might 
introduce incorrect information that could lead to medical 
errors. Second, perturbing the entire database (e.g., suffi-
cient statistics) might be useful for hypothesis testing and 
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machine learning but individual trajectories of the medical 
records might be destroyed. A recent study proposes the 
concept of “personalized privacy” [15], which allows indi-
viduals to set their own thresholds to determine the degree 
of protection. However, these methods do not consider the 
“event-level privacy” of individual patients as the meth-
ods do not discriminate different events of individual pa-
tients’ EHRs.   
The notion of event-level privacy has an interpretation 
from a novel perspective of computational phenotyping. 
Computational phenotyping is a method that aims to au-
tomatically mine or predict clinically significant (or scien-
tifically meaningful) phenotypes from structured EHR 
data, unstructured clinical narratives, or their combina-
tions. In medicine, the term phenotype refers to observable 
properties of a cohort of patients based on the interactions 
of their genotypes and the environment [16]. The goal of 
computational phenotyping is to extract a phenotype from 
complex and heterogeneous data sources and/or to pre-
dict clinically important phenotypes before they are actu-
ally observed. Depending on the nature of the task, com-
putational phenotyping can be formulated as either an un-
supervised or supervised learning problem. As summa-
rized in the review by Shivade et al. [17], supervised com-
putational phenotyping studies are provided with prede-
fined phenotypes, and the task is to identify a patient co-
hort matching the definition’s criteria. Many of these stud-
ies relied heavily on structured and coded patient data, 
where structured data typically capture patients’ events of 
laboratory test results, medication prescriptions, and pro-
cedure codes [18]. Event-level privacy protection can be 
viewed as a supervised computational phenotyping task 
where the sensitive disease event is the phenotype (e.g., 
ICD9 code 311). To ensure event-level privacy, our task is 
to obliterate events in the data that would allow the iden-
tification of sensitive disease events. Conventional compu-
tational phenotyping strives for high performance (e.g. 
Area Under the ROC Curve), while event-level privacy 
protection favors low identifiability. The models are fur-
ther complicated by heterogeneous data sources such as 
those from multiple instituions [17]. To take the data het-
erogeneity factor into consideration, in this study, we de-
liberately collect our patient EHRs from two hospitals. 
2 METHODS 
2.1 Sensitive disease list 
We selected 13 sensitive diseases as shown in Table 1. The 
list of sensitive diseases was categorized into 6 groups, in-
cluding Sexually transmitted diseases, Mental Diseases, 
Drug Addiction/Abuse, Male Reproductive Related, Fe-
male Reproductive Related, and Diseases of Newborn. 
This list includes typical diseases of each categories. 
Though not comprehensive, we believe that the list serves 
a proof-of-concept to understand the sensitivity of differ-
ent diseases that are common in EHRs. 
Table 1 Sensitive disease ICD9 codes, cohort sizes, descriptions, and 
the categories. 
ICD9 
Number of 
Patients Description Category 
042 2462 
Human immunode-
ficiency virus (HIV) Sexually transmit-
ted diseases 
 
099 945 
Other venereal dis-
eases 
300 5000 
Anxiety, dissocia-
tive and somato-
form disorders 
Mental Diseases 
311 5000 
Depressive disor-
der, not elsewhere 
classified 
304 2540 Drug dependence 
Drug Addic-
tion/Abuse 
 
305 5000 
Nondependent 
abuse of drugs 
306 1645 
Physiological mal-
function arising 
from mental factors 
606 3142 Infertility, male  Male reproduc-
tive related 607 5000 Disorders of penis 
626 5000 
Disorders of men-
struation and other 
abnormal bleeding 
from female genital 
tract 
Female reproduc-
tive related 
 
628 5000 Infertility, female 
768 164 
Intrauterine hy-
poxia and birth as-
phyxia Diseases of New-
born 
 
770 5000 
Other respiratory 
conditions of fetus 
and newborn 
 
2.2 Cohort selection 
We construct various sensitive disease patient cohorts and 
the non-sensitive disease patient cohort (consisting of pa-
tients without any diagnosis in the sensitive disease cate-
gory) by querying Northwestern Medicine® Enterprise 
Data Warehouse (NMEDW). The NMEDW is a joint initia-
tive across the Northwestern University Feinberg School of 
Medicine and Northwestern Memorial HealthCare [19]. 
NMEDW hosts a comprehensive and integrated repository 
of all clinical and research data sources from two hospitals: 
Northwestern Memorial Hospital (NMH) and Lake Forest 
Hospital (LFH). We use the following logic to construct the 
sensitive disease patient cohorts. For a particular ICD9 di-
agnosis code, we include all patients whose first diagnosis 
with the particular ICD9 code occurs between 10/1/2010 
and 9/30/2015. We restrict the sample to active patients of 
NMH or LFH and randomly select 5,000 such patients if 
returned cohort is larger than 5,000 (see Table 1 for details). 
Most of the cohort sizes are on this order of magnitude. We 
kept the sample size roughly constant to eliminate the pos-
sible influence of the sample size on the classification re-
sults. When selecting the non-sensitive disease cohort, we 
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note that many patients do not have any diagnoses codes 
associated with them (e.g., many healthy patients come to 
NMH or LFH for a physical examination). We thus further 
require that the patients must have at least one diagnosis 
code. For non-sensitive disease cohort, we randomly select 
30,000 patients who visited NMH or LFH between 
10/1/2010 and 9/30/2015 and never had a diagnosis listed 
as a sensitive disease. The patients with sensitive diseases 
often have many diagnoses, as shown in Figure 1 (a). Fig-
ure 1 (b) shows that even when we require the patients in 
the non-sensitive disease cohort to have at least one diag-
nosis, the distribution of diagnosis counts tends to skew 
towards the lower end compared to sensitive disease co-
horts (e.g., Figure 1 (a)). The differences in the diagnosis 
counts between sensitive disease patient cohorts and non-
sensitive disease cohort may introduce bias to the classifi-
cation in the sense that a seemingly good or bad classifier 
in fact is influenced by the fact that some patients have 
more comorbid conditions while other patients have fewer 
comorbidities. To offset this bias, we conduct stratified 
sampling of patients from non-sensitive disease collection 
by matching the percentages of patients with a comparable 
number of diagnoses in the non-sensitive disease cohort to 
those from the unionized sensitive disease cohort. 
 
(a) 
(b) 
Figure 1 Distribution of number of diagnoses for patients in the cohort 
with an ICD9 code 300 (Anxiety, dissociative and somatoform disor-
ders) and in the cohort without sensitive diseases. Both panels show 
distribution before random sampling. 
2.3 Feature collection 
We use the patients’ laboratory test results, medications 
and procedures as their features. For a particular feature, 
we extract all measurements and records across a patient’s 
entire medical record history. This is to support a worst-
case analysis as there may be no limitation on what can be 
included in the dataset released for secondary analyses. 
We use binary encoding to represent the features. For la-
boratory test results, we compare their values with the cor-
responding low and high reference ranges presented in 
NMEDW. For example, if the Blood Urea Nitrogen (BUN) 
value is below low reference value, we set BUN_low to 1 
and BUN_high to 0. With this binary encoding, the lab fea-
tures should be interpreted as whether a patient has had 
an abnormally low or high value for a particular lab test. 
We apply similar binary encoding to medications, proce-
dures, and non-sensitive diagnoses to capture whether a 
patient has taken a medication, has undergone a 
procedure, or has a comorbidity. The feature dimensions 
for the sensitive disease and non-sensitive disease cohorts 
are shown in Table 2. 
 
Table 2 Number of features for sensitive disease and non-sensitive 
disease cohorts with matching diagnosis count (nonsd_match). Note 
that the total feature number for a particular cohort is 2×lab + proce-
dure + med, because for each lab, there are 2 features: low and high. 
ICD9 Medication Procedure Lab Comorbidity 
042 1768 2071 806 804 
099 1219 1515 468 619 
300 2274 3005 992 882 
304 1843 2385 908 865 
305 1994 2643 896 883 
306 1790 2311 724 760 
311 2339 3110 997 897 
606 1338 1801 601 667 
607 2172 2936 935 858 
626 1998 2531 837 780 
628 1782 2339 725 738 
768 511 465 359 362 
770 683 709 516 490 
nonsd_m
atch 
2912 4099 1079 952 
 
2.4 Dataset construction 
When an EHR-based dataset is released for secondary 
analyses, the dataset typically contains a mixture of pa-
tients with sensitive diseases and with non-sensitive dis-
eases. What immediately compromises privacy is a secu-
rity attacker’s ability to identify patients with a particular 
sensitive disease (e.g. Drug dependence with ICD9 code of 
304). We approximate this scenario by using each sensitive 
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disease (e.g. ICD9 code 304) as the case group, and leaving 
the rest of the sensitive diseases and the non-sensitive dis-
ease cohorts as the control group. We then perform a su-
pervised classification on the case and control groups. We 
anticipate that, when trying to identify a particular sensi-
tive disease (the case), attackers will have limited amount 
of training data (e.g., by annotating a few cases and control 
themselves). Thus, during cross validation, we perform 
stratified split of the entire dataset into the training and test 
datasets, according to a 1:9 ratio. Such a ratio maps to 
about 500 case- and 3000 + 500*12 control- patients being 
annotated, which is a significant annotation effort even for 
a deliberated attacker. 
2.5 Classification 
We use logistic regression with 𝑙𝑙2 norm regularization to 
classify whether a patient belongs to a particular sensitive 
disease cohort. Logistic regression is chosen as the classifi-
cation model due to its popularity in the machine learning 
and statistics community. Logistic regression aims to max-
imize the conditional likelihood of the class label given the 
features of a patient, as shown in equation ( 1 ). For an in-
stance 𝑥𝑥 in equation ( 1 ), 𝑓𝑓𝑖𝑖(𝑥𝑥) denotes its 𝑖𝑖th feature, 𝑤𝑤𝑖𝑖𝑖𝑖 is 
the weight associated with 𝑖𝑖th feature and 𝑐𝑐th class. For bi-
nary classification problem, we often set 𝑤𝑤𝑖𝑖0 = 0, simplify 
the notation of 𝑤𝑤𝑖𝑖1 to 𝑤𝑤𝑖𝑖  and reduce the weights to a vector 
𝒘𝒘.  
𝑝𝑝(𝑐𝑐|𝑥𝑥) = exp�∑ 𝑤𝑤𝑖𝑖𝑖𝑖𝑓𝑓𝑖𝑖(𝑥𝑥)𝐿𝐿𝑖𝑖=1 �
∑ exp�∑ 𝑤𝑤𝑖𝑖𝑖𝑖′𝑓𝑓𝑖𝑖(𝑥𝑥)𝐿𝐿𝑖𝑖=1 �𝐶𝐶𝑖𝑖′=0    ( 1 ) 
Maximizing the conditional probability for all training 
instances is equivalent to minimizing the summation of 
negative log-likelihood for all instances, as shown in equa-
tion ( 2 ): 
−� log �𝑝𝑝�𝑐𝑐𝑗𝑗�𝑥𝑥𝑗𝑗��𝑁𝑁
𝑗𝑗=1
+ 𝜆𝜆‖𝒘𝒘‖2  ( 2 ) 
The term 𝜆𝜆‖𝒘𝒘‖2 in equation ( 2 ) is the regularization term, 
which is added in order to avoid overfitting. Here we use 
the 𝑙𝑙2-norm of the weight vector 𝑤𝑤  as a gauge of model 
complexity. In this experiment, we choose 𝜆𝜆 = 1.  
2.6 Feature ablation 
Feature selection is a standard practice of tuning machine 
learning models. In this study, we try to identify important 
features that are most predictive for sensitive diseases, and 
remove them (hence using the term feature ablation). Uni-
variate feature selection is a common choice for feature se-
lection. Univariate feature selection typically works by 
computing a score that indicates the predicting power of a 
feature. In this study, we use the 𝜒𝜒2 statistic between each 
feature and the class label as the feature scores for classifi-
cation tasks, as shown in equation ( 3 ). Note that in our 
experiment, we adopt binary classification and binary fea-
tures. In equation ( 3 ), 𝑐𝑐 denotes the index for class lable, 
𝑓𝑓  denotes the feature value; 𝑝𝑝𝑖𝑖𝑐𝑐  is the percentage of pa-
tients with class 𝑐𝑐 and feature value 𝑓𝑓; 𝑛𝑛 is the total num-
ber of patients; 𝑝𝑝𝑖𝑖⋅ = ∑ 𝑝𝑝𝑐𝑐𝑓𝑓1𝑓𝑓=0𝑛𝑛  and 𝑝𝑝⋅𝑐𝑐 = ∑ 𝑝𝑝𝑐𝑐𝑓𝑓1𝑐𝑐=0𝑛𝑛  are the per-
centages of patients with class 𝑐𝑐 and feature value 𝑓𝑓, re-
spectively:  
𝜒𝜒2 = ���𝑝𝑝𝑖𝑖𝑐𝑐 − 𝑝𝑝𝑖𝑖⋅𝑝𝑝⋅𝑐𝑐�2
𝑝𝑝𝑖𝑖⋅𝑝𝑝⋅𝑐𝑐/𝑛𝑛1𝑐𝑐=01𝑖𝑖=0   ( 3 ) 
Intuitively, the higher the 𝜒𝜒2 statistic, the more closely the 
the feature 𝑓𝑓 is related to the corresponding class label 𝑐𝑐. 
Thus the 𝜒𝜒2 statistic can be used as the feature score.  
Besides the 𝜒𝜒2 statistic, other metrics can also be used 
as feature scores. The ANOVA F-test statistic is the ratio of 
between-group variability and with-in group variability. 
In the following formula, the numerator and denominator 
are the between-group variability and with-in group vari-
ability, respectively, 
𝐹𝐹 = ∑ 𝑛𝑛𝑖𝑖�𝑓𝑓𝑖𝑖 − 𝑓𝑓�21𝑖𝑖=0 /(2 − 1)
∑ ∑ �𝑓𝑓𝑖𝑖𝑗𝑗 − 𝑓𝑓𝑖𝑖�
2/(𝑛𝑛 − 2)𝑛𝑛𝑐𝑐𝑗𝑗=11𝑖𝑖=0  ( 4 ) 
where 𝑓𝑓𝑖𝑖  and 𝑓𝑓  respectively denote the sample mean of 
the feature values in group 𝑐𝑐 and overall mean of the fea-
ture values for all patients respectively; 𝑛𝑛𝑖𝑖 is the number of 
patients in group 𝑐𝑐; 𝑛𝑛 is the total number of patients; 𝑓𝑓𝑖𝑖𝑗𝑗 is 
the binary feature value for the 𝑗𝑗th patient in group 𝑐𝑐. In-
tuitively, a predictive feature can effectively separate the 
groups, so it should have a small with-in group variability 
and a large between-group variability, and hence a larger 
F-test statistic. Thus the higher the F statistic is, the more 
predictive the feature is. In this study, we select features 
based on the 𝑘𝑘  highest feature scores. For 𝑘𝑘 =10, 20, … ,50, 100, 200, … , 1000 , we delete the k-best fea-
tures in an iterative manner, and evaluate the classification 
performance on the remaining features. 
2.7 Evaluation metrics 
To evaluate the performance of our classification models 
and the impact of feature ablation, we plot the Receiver 
Operating Characteristic (ROC) curve and compute the 
Area Under the ROC curve (AUC), along with metrics in-
cluding precision, recall, and F-measure. Let 𝑇𝑇𝑇𝑇  be the 
number of true positives, 𝐹𝐹𝑇𝑇 the number of false positives, 
and 𝐹𝐹𝐹𝐹 the number of false negatives. We can use the fol-
lowing equations to calculate precision, recall, and F-meas-
ure: 
𝑇𝑇𝑃𝑃𝑃𝑃𝑐𝑐𝑖𝑖𝑃𝑃𝑖𝑖𝑃𝑃𝑛𝑛 = 𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝑇𝑇 ( 5 ) 
𝑅𝑅𝑃𝑃𝑐𝑐𝑅𝑅𝑙𝑙𝑙𝑙 = 𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹 ( 6 ) 
𝐹𝐹 measure = 2 ⋅ 𝑇𝑇𝑃𝑃𝑃𝑃𝑐𝑐𝑖𝑖𝑃𝑃𝑖𝑖𝑃𝑃𝑛𝑛 ⋅ 𝑅𝑅𝑃𝑃𝑐𝑐𝑅𝑅𝑙𝑙𝑙𝑙
𝑇𝑇𝑃𝑃𝑃𝑃𝑐𝑐𝑖𝑖𝑃𝑃𝑖𝑖𝑃𝑃𝑛𝑛 + 𝑅𝑅𝑃𝑃𝑐𝑐𝑅𝑅𝑙𝑙𝑙𝑙  ( 7 ) 
2.8 Random Simulation 
We hypothesize that in addition to lab tests, medications 
and procedures that are unique to sensitive diseases, the 
percentage differences between case and control on over-
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lapping features may also play a key role in the identifia-
bility of sensitive diseases. To test this hypothesis, we per-
form two random simulation experiments. In each of the 
experiments, we randomly generate a binary feature ma-
trix with the same size as the corresponding real-data ma-
trix that combines the case and the control. Each row of the 
matrix corresponds to a patient, and each column corre-
sponds to a feature. In the random feature matrix, feature 
values are randomly generated from a binomial distribu-
tion: the number of 1’s (denoted as 𝑘𝑘) for a particular fea-
ture has the following probability �𝑛𝑛𝑘𝑘� 𝑝𝑝
𝑘𝑘(1 − 𝑝𝑝)𝑛𝑛−𝑘𝑘, where 
𝑛𝑛 is the total number of patients and 𝑝𝑝 is the probability of 
1 for the particular binary feature. The simulations aim to 
approximate the two extreme situations regarding the dif-
ferences of parameter 𝑝𝑝. In the first simulation, for the 𝑖𝑖th 
feature, the case and the control have the same probability 
𝑝𝑝𝑖𝑖 , drawn from a uniform [0,1] distribution; while in the 
second simulation, for the 𝑖𝑖th feature, the case and the con-
trol have probabilities 𝑝𝑝𝑖𝑖𝑖𝑖𝑐𝑐𝑐𝑐𝑐𝑐  and 𝑝𝑝𝑖𝑖𝑖𝑖𝑐𝑐𝑐𝑐𝑐𝑐 , drawn inde-
pendently from a uniform [0,1] distribution. We then fol-
low the same classification model and configuration (e.g., 
train:test split) as described above. The ROC curves for the 
two simulations and the real-data classifications are shown 
in Figure 2. From the figure, we see that: when the majority 
of the features have different 𝑝𝑝  parameters for case and 
control, the sensitive disease patients can be perfectly iden-
tified; when each feature has the same 𝑝𝑝 parameters for 
case and control, the sensitive disease patients are non-
identifiable. In reality, there are a small fraction of features 
with different 𝑝𝑝 parameters between case and control, and 
the bigger the fraction is, the more identifiable the sensitive 
disease paitents are. 
a1 b1 c1 
a2 b2 c2 
Figure 2 Random Simulations of identifiability of 3 typical sensitive diseases under different feature value distributions: ICD9 300 Anxiety, 
dissociative and somatoform disorders; ICD9 626 Disorders of menstruation and other abnormal bleeding from female genital tract; ICD9 770 
Other respiratory conditions of fetus and newborn. Panels a1, b1, and c1 show ROC curves of the two random simulations and the real-data 
classification results using all features. Panels a2, b2, and c2 show the difference of percentages of 1’s for each features ranked from low to 
high, for simulations and real data.  
3 EXPERIMENTS AND RESULTS 
As described in Section 2.3, our classification problem is 
formulated as distinguishing patients with a particular 
type of sensitive disease (case) from the patients without 
this sensitive disease (control). For a particular case control 
setting, we performed the following 10-fold cross 
validation. We equally split the data into 10 parts, with 
each part having the same number of case and control sam-
ples. We use each of one part for training, and the other 9 
parts for testing, so that the train-test ratio is 1:9. We repeat 
10 times to cover all of the case samples, and report the av-
erage of evaluation metrics. 
When the non-sensitive disease cohort is selected by 
matching the distribution of diagnosis counts to those in 
the sensitive disease cohorts, the results of classification 
AUC for each sensitive disease as a function of feature ab-
lations are shown in Table 3. The classification AUC curves 
can be grouped into 3 categories: (1) fast declining (AUC 
falls below 0.6 with less than 400 features excluded); (2) 
progressively declining (AUC falls below 0.7 with between 
200 and 700 features excluded), (3) slowly declining (AUC 
does not fall below 0.7 with 1000 features excluded). 5 dis-
eases (with ICD9 codes of 099, 300, 305, 306, 311) fall into 
the first category; 7 diseases (with ICD9 codes of 042, 304, 
606, 607, 626, 628, 768) belong to the second category; and 
1 disease (with ICD9 codes of 770) falls into the third cate-
gory. The separation of 3 categories demonstrates the di-
versity of the sensitive diseases regarding the difficulty in 
identifying them. The majority of the diseases (12 out of 13) 
belong to the first two categories, suggesting that feature 
ablation is effective or has the potential of reducing sensi-
tive disease identifiability.  
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Table 3 The impact of feature ablation on sensitive disease classification AUC with diagnosis-count-matching between sensitive and non-
sensitive disaese cohort. The top row indicates whether using all features or excluding a certain number of top features. Red shades indicate 
AUC less than 0.7, whereas above 0.7 AUC is generally regarded as modest classification performance. Green shades indicate AUC less than 
0.6, whereas 0.5 AUC means classification is no different than coin toss. 
ICD9 All 10 20 30 40 50 100 200 300 400 500 600 700 800 900 1000 
099 0.783 0.692 0.674 0.664 0.658 0.656 0.645 0.627 0.614 0.599 0.592 0.581 0.576 0.565 0.560 0.555 
300 0.676 0.606 0.591 0.585 0.582 0.576 0.565 0.553 0.542 0.536 0.530 0.523 0.518 0.515 0.512 0.507 
305 0.698 0.660 0.653 0.647 0.646 0.642 0.634 0.614 0.604 0.593 0.583 0.572 0.560 0.551 0.548 0.543 
306 0.739 0.640 0.619 0.608 0.599 0.593 0.574 0.558 0.547 0.540 0.535 0.534 0.526 0.521 0.520 0.515 
311 0.711 0.628 0.609 0.604 0.604 0.599 0.589 0.572 0.560 0.553 0.547 0.539 0.533 0.526 0.521 0.517 
042 0.914 0.862 0.836 0.824 0.815 0.802 0.760 0.722 0.697 0.680 0.658 0.643 0.635 0.628 0.617 0.617 
304 0.866 0.834 0.822 0.815 0.812 0.810 0.785 0.762 0.744 0.727 0.709 0.694 0.670 0.657 0.646 0.639 
606 0.910 0.834 0.773 0.755 0.747 0.747 0.734 0.716 0.699 0.686 0.673 0.660 0.642 0.631 0.626 0.612 
607 0.851 0.771 0.759 0.748 0.743 0.737 0.720 0.691 0.668 0.645 0.630 0.619 0.600 0.589 0.582 0.573 
626 0.826 0.809 0.796 0.788 0.783 0.780 0.758 0.730 0.694 0.672 0.658 0.648 0.634 0.618 0.609 0.599 
628 0.910 0.878 0.875 0.874 0.864 0.849 0.832 0.792 0.768 0.747 0.716 0.693 0.679 0.664 0.651 0.639 
768 0.834 0.833 0.832 0.835 0.834 0.832 0.840 0.840 0.818 0.779 0.756 0.725 0.698 0.668 0.642 0.620 
770 0.993 0.992 0.991 0.991 0.991 0.991 0.990 0.986 0.980 0.973 0.966 0.957 0.952 0.939 0.928 0.917 
Diseases with ICD9 codes 300 (Anxiety, dissociative 
and somatoform disorders), 626 (Disorders of menstrua-
tion and other abnormal bleeding from female genital 
tract), and 770 (Other respiratory conditions of fetus and 
newborn) are examples of sensitive diseases in each cate-
gory, with decreasing difficulties (or increasing likelihood) 
to identify. The AUC of ICD9 300 is only 0.676 even if no 
feature is deleted, and quickly drops toward 0.6 after re-
moving a few top features. The AUC of disease 626 is 0.826 
without deleting any features, and quickly decreases be-
low 0.8 after removing the top 20 features, and then drops 
below 0.7 after removing 300 features. Disease 770 starts 
with above 0.99 AUC and remains 0.9 after excluding 1000 
top features.  
Figure 3 shows the trends of precision, recall, F-meas-
ure, and AUC, under one random train:test split, as feature 
ablations progress for diseases with ICD9 code 300, 626, 
and 770, respectively. Three classification feature sets are 
used, including “union”, “control”, and “intersect”. The 
“union” feature set includes features occurred in either the 
case or the control cohort. The “control” feature set in-
cludes features in the control cohort. The “intersect” fea-
ture set includes features occurred in both the case and the 
control cohort. Figure 3 also shows the number of features 
in different feature sets. Clearly, the number of features are 
roughly equal to the “union” and the “control” feature 
sets. Intersecting features results in significant drop in the 
number of features. It is not surprising to see that intersect 
feature sets correspond to the fastest classification perfor-
mance decrease as there are (much) fewer features to begin 
with. Interestingly, diseases with fewer intersect features 
(when the case features overlap with fewer control fea-
tures) tend to have slower performance degradation as fea-
ture ablation progresses, which suggests that in those 
cases, classifications largely rely on control features.    
In general, for diseases in the first category (e.g., ICD9 
300), they start with only moderate AUC. In addition, their 
precision, recall and F-measure start low (e.g., precision 
below 0.2, recall and F-measure below 0.1 for ICD9 300). 
For diseases in the second category (e.g., ICD9 626), they 
start with high AUC. Besides, their precision, recall and F-
measure start with modest values (e.g., precision around 
0.5, recall around 0.3, and F-measure around 0.4 for ICD9 
626). But their precision, recall and F-measure quickly drop 
when we delete a small number of top features (e.g., 30 top 
features for ICD9 626). For diseases in the third category 
(e.g., ICD9 770), they start with over 0.99 AUC. Moreover, 
their precision, recall and F-measure start high and gradu-
ally decrease as feature ablation progresses. It is interesting 
to note that even when AUCs are high above 0.8, the F-
measure are only modest (e.g., 0.4 for ICD9 626). In fact, 
the first and second disease categories both seem to 
demonstrate reasonable non-identifiability for sensitive 
disease patients with moderate feature ablation efforts.  
When the non-sensitive disease cohort is selected by re-
quiring each patient has at least one diagnosis, the results 
of classification AUC for each sensitive disease as feature 
ablation progress are shown in Table 4. Compared to Table 
3, Table 4 does not require diagnosis count matching hence 
is more relaxed. Table 4 demonstrates similar category 
structures of sensitive diseases regarding difficulty in iden-
tifying them. The values in Table 4 are similar to those in 
Table 3, suggesting that the classification performance is 
not very sensitive to whether the number of diagnoses is 
matched between sensitive and non-sensitive disease co-
horts. Such insensitivity will likely save the effort for 
matching the severity between the patients with and with-
out sensitive diseases (such effort may artificially alter 
patient distribution and introduce bias) when releasing the 
dataset for secondary analysis and preserving the non-
identifiability of sensitive disease patients. An additional 
observation regarding both settings is that when ablating 
1,000 out of a total of over 13,000 features (<8%), the pre-
dictability of most sensitive diseases is reduced (to <0.7 
AUC) and many are close to poorly predictable (to <0.6 
AUC).
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Figure 3 Trends of evaluation metrics as feature ablation progresses for three representative sensitive diseases: ICD9 300 Anxiety, dissociative 
and somatoform disorders; ICD9 626 Disorders of menstruation and other abnormal bleeding from female genital tract; ICD9 770 Other respir-
atory conditions of fetus and newborn. The panels a1 through a4 correspond to precision, recall, F-measure and AUC for ICD9 code 300, b1 
through b4 correspond to ICD9 code 626, and c1 through c4 correspond to ICD9 code 770, respectively. Three classification feature sets are 
used, including “union”, “control”, and “intersect”. The “union” feature set includes features occurred in either the case or the control cohort. The 
“control” feature set includes only features in the control cohort. The “intersect” feature set includes features occurred in both the case and the 
control cohort. Also shown in the legend of the figures are the number of features. 
Table 4 The impact of feature ablation on sensitive disease classification AUC without diagnosis-count-matching between sensitive and non-
sensitive disease cohort. Each patient in the non-sensitive disease cohort contains at least one diagnosis. The top row indicates whether using 
all features or excluding a certain number of top features. Red shades indicate AUC less than 0.7, whereas above 0.7 AUC is generally regarded 
as modest classification performance. Green shades indicate AUC less than 0.6, 0.5 AUC means classification is no different than coin toss. 
ICD9 All 10 20 30 40 50 100 200 300 400 500 600 700 800 900 1000 
099 0.779 0.696 0.655 0.641 0.635 0.631 0.618 0.617 0.601 0.592 0.579 0.569 0.560 0.555 0.549 0.536 
300 0.671 0.606 0.589 0.585 0.579 0.577 0.565 0.557 0.552 0.545 0.537 0.531 0.527 0.522 0.519 0.514 
305 0.683 0.646 0.639 0.636 0.634 0.630 0.620 0.609 0.593 0.581 0.571 0.560 0.551 0.544 0.537 0.529 
306 0.748 0.645 0.626 0.616 0.605 0.602 0.582 0.576 0.565 0.554 0.546 0.538 0.535 0.532 0.526 0.521 
311 0.706 0.633 0.609 0.605 0.601 0.597 0.585 0.581 0.578 0.569 0.560 0.552 0.547 0.538 0.531 0.526 
042 0.910 0.858 0.829 0.817 0.809 0.787 0.750 0.723 0.706 0.682 0.658 0.644 0.623 0.611 0.596 0.591 
304 0.857 0.824 0.809 0.804 0.793 0.791 0.768 0.754 0.744 0.722 0.705 0.691 0.664 0.649 0.634 0.622 
606 0.915 0.835 0.764 0.744 0.735 0.733 0.716 0.706 0.698 0.680 0.652 0.641 0.625 0.620 0.611 0.597 
607 0.858 0.785 0.773 0.762 0.759 0.756 0.737 0.725 0.719 0.687 0.662 0.650 0.635 0.619 0.609 0.597 
626 0.817 0.801 0.782 0.776 0.767 0.759 0.741 0.718 0.704 0.672 0.652 0.640 0.627 0.604 0.593 0.582 
628 0.910 0.874 0.871 0.870 0.858 0.844 0.826 0.808 0.786 0.739 0.713 0.696 0.682 0.666 0.648 0.636 
768 0.802 0.801 0.800 0.801 0.798 0.799 0.800 0.797 0.792 0.781 0.747 0.706 0.668 0.643 0.618 0.596 
770 0.992 0.988 0.988 0.988 0.988 0.988 0.986 0.985 0.980 0.973 0.964 0.953 0.943 0.929 0.915 0.894 
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(a) 
(b) 
(c) 
Figure 4 Top feature category percentage as feature ablation pro-
gresses. 
Figure 4 shows the category (lab, medication, proce-
dure features) percentage of excluded features as feature 
ablation progresses with increasing number of features. 
For most sensitive diseases in the first category, medication 
often rank as top features. For most sensitive diseases with 
slowly declining AUCs, lab features often play an im-
portant role. For sensitive diseases in the second category, 
the situation is more complex, each category of features 
may dominate the classification performance (e.g., proce-
dures dominate top features for ICD9 626). Moreover, 
about 20% of ablated features are co-morbidity at the abla-
tion level of 1000. Co-morbidity ablation seems to be the 
less compared to lab, procedure and medication features, 
across the three categories of ablation trends. Admittedly, 
losing comorbidities will make individual trajectories in-
complete. However, an incomplete patients records might 
still have significant usefulness to researchers. For exam-
ple, for the retained comorbidities which account of 
majority of comorbidities, their co-occurrence patterns and 
statistics will still be preserved. Hence the sensitive infor-
mation ablated patients records should still be valuable to 
research targeting non-sensitive comorbidities. 
Figure 5 shows 𝜒𝜒2 feature scores and ANOVA F-test 
feature scores for the representative sensitive diseases. It is 
consistent with the intuition that sensitive diseases with 
faster decreasing AUCs have lower feature scores for top 
features. For example, ICD9 300 begins with 𝜒𝜒2  feature 
scores less than 104 and ANOVA F-test feature scores but 
ICD9 626 and 770 begin with feature scores more than 104. 
In addition, sensitive diseases with slower decreasing 
AUCs tend to have slower decreasing feature scores. For 
example, at round 1000th feature for ICD9 626, the 𝜒𝜒2 fea-
ture scores and ANOVA F-test feature scores drop to 10; 
while at around 2000th feature for ICD9 770, the 𝜒𝜒2 feature 
scores and ANOVA F-test feature scores drop to 10. Also, 
to note that, the features in Figure 5 are ranked in descend-
ing order of 𝜒𝜒2 feature scores in order to visually illustrate 
the different rankings of 𝜒𝜒2 feature scores and ANOVA F-
test feature scores. In ANOVA F-test feature scores, there 
are only slight jitterings of the scores, demonstrating that 
𝜒𝜒2 feature scores and ANOVA F-test feature scores largely 
agree with each other. It is for this reason that we only 
show the feature ablation results with ablation order based 
on 𝜒𝜒2 feature scores in Table 3, Table 4, Figure 3 and Figure 
4, because the feature ablation results with ablation order 
based on ANOVA F-test feature scores are very similar. 
Table 5 shows the top features for classifying the three 
representative diseases according to 𝜒𝜒2 feature scores. For 
ICD9 300 (Anxiety, dissociative and somatoform disor-
ders), the top features are popoulated by anti-anxiety or 
anti-depression medications such as alprazolam, 
clonazepam, escitalopram etc; for ICD9 626 (Disorders of 
menstruation and other abnormal bleeding from female 
genital tract), the top features include female reproductive-
system-related procedures, medications, and cormobidi-
ties. Finally, for ICD9 770 (Other respiratory conditions of 
fetus and newborn), we see labs and procedures specifi-
cally for neonates as well as medications such as Zinc Ox-
ide which can treat and prevent diaper rash. In general, 
many of these features are uniquely associated with the 
specific sensitive diaseases, which partly explains the 
higher feature scores for the top few features as shown in 
Figure 5. 
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Figure 5 Feature scores for representative sensitive diseases: ICD9 300 Anxiety, dissociative and somatoform disorders; ICD9 626 Disorders 
of menstruation and other abnormal bleeding from female genital tract; ICD9 770 Other respiratory conditions of fetus and newborn. Panels a1, 
b1, c1 show the 𝜒𝜒2 feature scores, while panels a2, b2, c2 show the ANOVA F-test feature scores. The features are ranked according to 
descending order of 𝜒𝜒2 feature scores in order to visually illustrate the different rankings of 𝜒𝜒2 feature scores and ANOVA F-test feature scores.  
Table 5 Top 10 features for representative sensitive diseases: ICD9 300 Anxiety, dissociative and somatoform disorders; ICD9 626 Disorders 
of menstruation and other abnormal bleeding from female genital tract; ICD9 770 Other respiratory conditions of fetus and newborn. 
ICD9 300 ICD9 626 ICD9 770 
Med_alprazolam Comor_218 Comor_V30 
Med_escitalopram Procedure_us pelvis complete Lab_low_bedside glucose 
Med_clonazepam Comor_625 Med_vitamin k 1 
Med_lorazepam Med_bupivacaine-fentanyl Med_erythromycin 
Med_sertraline Procedure_obstetrical ultrasound Med_ampicillin 
Med_citalopram Med_oxytocin Comor_V29 
Comor_780 Med_lanolin Lab_high_bilirubin-neona-
tal 
Med_bupropion Med_glycerin-witch hazel Lab_high_bilirubin neona-
tal 
Comor_V70 Med_benzocaine Med_zinc oxide 
Med_fluoxetine Comor_V25 Lab_low_glucose 
 
4 DISCUSSION AND FUTURE WORK 
Our results show that patients with different sensitive dis-
eases have different identifiability and therefore their pro-
tection deserves customized efforts. Event-level privacy 
protection for some of the sensitive diseases requires re-
moving a few related features but others require ablating 
many more. This study provides evidence to develop cus-
tomized event-level privacy-preserving mechanisms and 
offer fine-grained protection. Comparing to the traditional 
de-identification method, ours provides an extra layer of 
protection by redacting events associated with the sensi-
tive diseases so that even linkage attack for re-identifica-
tion [20, 21] cannot reveal the diseases of concern to indi-
vidual patients. 
Our study also comes with several limitations. In our 
study, we selected the relatively prevalent sensitive dis-
eases that produce more than 5000 patients during the ret-
rospective time window between 10/1/2010 and 
9/30/2015. However, there are other diseases that are sen-
sitive but less prevalent. The classification tasks for identi-
fying less prevalent sensitive diseases may present unique 
challenges in both model selection and feature engineer-
ing. For example, when there are only a few positive labels, 
the classification tasks may be formulated as an anomaly 
detection problem. In addition, although the evaluation is 
based on the data from two hospitals, they are from the 
same region (Chicago area) and may present only limited 
geographic diversity. We plan to test our findings from 
multiple institutions in research network setting [22] at 
national scale and check the consistency of the results. 
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In this study, we formulated the features as whether 
or not the patient has experienced a high/low lab test re-
sult, whether the patient has taken a certain medication, 
and whether a certain procedure has been performed on 
the patient. Feature ablation under this formulation will 
eliminate all occurrences of a particular lab test being 
high/low, all history of a particular medication, or all his-
tory of a particular procedure. One can choose to keep the 
timestamps of the features and increase the granularity of 
the event in order to preserve more medical events that oc-
curred at other times and are not predictive of the sensitive 
disease a patient may have. In reality, attackers may also 
employ imputation methods and potentially obtain more 
abnormal lab test results, with and without timestamps 
[23, 24]. From this perspective, the fine-grained event-level 
privacy protection with attackers having imputation capa-
bility presents more challenges. However, even in finer 
grained event-level privacy protection, the formulation 
and results of our study cannot be bypassed because at-
tackers can always reduce the problem to our formulation 
in order to have less sparse features and potentially better 
identifiability. We plan to systematically study such trade-
offs as a next step. 
This study provides a proof-of-concept feature abla-
tion framework towards event-level privacy protection. 
We envision the integration of such fine-grained protection 
mechanism with informed consent to patients would en-
courage data sharing without compromising their privacy. 
We chose logistic regression with 𝑙𝑙2-norm regularization 
as the classification model due to its popularity in both the 
machine learning and statistics community. Our feature 
ablation framework is general and applies to other classifi-
cation models such as support vector machines, artifial 
neural networks, decision trees, random forests and Bayes-
ian networks. One can also choose from other regulariza-
tions such as 𝑙𝑙1-norm regularization. On the other hand, at-
tackers may employ feature dimensionality reduction 
techniques when feature matrix is sparse [25, 26], or choose 
to model different categories of features using a tensor [27-
31] to explore feature interaction, or use deep learning 
methods [32, 33], in order to improve the classification per-
formance. The exact performances by using other classifi-
cation models, regularizations, feature formulation and 
learning, are expected to vary depending on the combina-
tions to be used. Future studies are encouraged to explore 
the above combinations of alternatives and better charac-
terize the feasibility and the efficacy for the broader terri-
tory of event-level privacy protection. We have not inte-
grated event-level privacy protection in a daily clinical 
workflow and will investigate the pipeline of this method 
at work in a real-world scenario in the future. 
5 CONCLUSION 
We conduct a study of event-level privacy protection, 
which might have the potential to provide customized pro-
tection of individuals’ data. We demonstrated that patients 
with different sensitive diseases have different identifiabil-
ity and therefore their protection deserves different 
mechanisms. We developed a new and intuitive feature 
ablation method to protect event-level privacy. From a 
group of sensitive diagnoses, we evaluated the feasibility 
and the efficacy of our proposed method. As feature abla-
tion progresses, the AUCs decrease with varying speeds, 
for classifying patients with sensitive disease vs. other pa-
tients. The sensitive diseases can be divided into 3 catego-
ries according to the trends that feature ablation decreases 
their identifiability: fast declining (AUC falls below 0.6 
with less than 400 features excluded), progressively declin-
ing (AUC falls below 0.7 with between 200 and 1000 fea-
tures excluded), slowly declining (AUC does not fall below 
0.7 with 1000 features excluded). The fact that the majority 
(12 out of 13) of the sensitive diseases fall into the first two 
categories suggests the practical applicability or potential 
of feature ablation for event-level privacy protection.  
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